OHI
Omega Healthcare InvestorsDAI scenario view
RankAlpha Sentiment CodexAI sentiment snapshot
AI commentary
Headline flow is high because Omega reported earnings on April 28, 2026 and filed its 10-Q on April 29, 2026. Primary-source evidence supports a better quarter and a guidance midpoint increase, but the stock traded at $46.29 on April 29 versus the $47.42 April 28 anchor, indicating a mildly negative market read after the print. The peer frame has been narrowed to healthcare and skilled-nursing REITs, but current direct-peer valuation spreads and a clear wave of post-earnings analyst revisions were not confirmed by April 29, so this remains a cautious monitoring view rather than a standard-conviction rerating call.
Evidence flagged
memo remains a monitoring view with limited forward evidence and should not be standard-conviction
AI events
Omega reported Q1 2026 AFFO of $0.82 per diluted share versus $0.75 a year earlier, completed $251 million of Q1 investments, and raised full-year AFFO guidance to $3.19-$3.25 from $3.15-$3.25; despite that, shares traded about 2.4% below the prior close on April 29, 2026, suggesting the good print was only partly credited and tenant-risk questions remain [#8-K-2026-04-28].
Omega said 12 Maryland facilities were sold in April 2026 and the remaining six West Virginia CommuniCare facilities are expected to sell in Q2 2026 for an aggregate contractual purchase price near $480 million; completing that disposition would monetize assets tied to 0.87x trailing EBITDAR coverage and support redeployment or deleveraging [#8-K-2026-04-28].
Guidance assumes Genesis continues paying its full $13.3 million quarterly contractual rent, Maplewood pays about $19.5 million per quarter, and Omega converts recent acquisitions and loans into sustained AFFO growth; Q1 investments carried roughly 10%-13% initial yields, but the thesis still depends on operator health and execution [#8-K-2026-04-28].
Recommendation
No formal recommendation provided.

